Apallergy.2013.3.2.127. 89. O’Hara J, Jones N. ” Post-nasal drip syndrome”: most individuals with purulent nasal secretions usually do not complain of chronic cough. Rhinology. 2006;44(4):270.90. Tatar M, Plevkova J, Brozmanova M, Pecova R, Kollarik M. Mechanisms of the cough related to rhinosinusitis. Pulm Pharmacol Ther. 2009;22(two):121. doi:ten.1016j.pupt.2008.11.014. 91. Pecova R, Vrlik M, Tatar M. Cough sensitivity in allergic rhinitis. J Physiol Pharmacol. 2005;56 Suppl 4:171. 92. Plevkova J, Poliacek I, Antosiewicz J, Adamkov M, Jakus J, Svirlochova K, et al. Intranasal TRPV1 agonist capsaicin challenge and its impact on c-fos expression in the guinea pig brainstem. Respir Physiol Neurobiol. 2010;173(1):11. doi:10.1016j.resp.2010.05.015. 93. Buday T, Brozmanova M, Biringerova Z, Neu-P11 Purity & Documentation Gavliakova S, Poliacek I, Calkovsky V, et al. Modulation of cough response by sensory inputs in the nose – function of trigeminal TRPA1 versus TRPM8 channels. Cough. 2012;8(1):11. doi:ten.11861745-9974-8-11. 94. Yancy Jr WS, McCrory DC, Coeytaux RR, Schmit KM, Kemper AR, Goode A, et al. Efficacy and tolerability of remedies for chronic cough: a systematic assessment and meta-analysis. Chest. 2013;144(six):18278. doi:ten.1378chest.13-0490. 95. Morice AH, Menon MS, Mulrennan SA, Everett CF, Wright C, Jackson J, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med. 2007;175(4):312. doi:ten.1164rccm.200607-892OC. 96. Dickinson R, Morjaria J, Wright C, Morice A. Is opiate action in cough as a result of sedation Ther Adv Chronic Dis. 2014;5(five):200. 97. Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9853):1583. 98. Faruqi S, Wright C, Thompson R, Morice AH. A randomized placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy Acei Inhibitors MedChemExpress volunteers. Br J Clin Pharmacol. 2014;78(6):12720. doi:ten.1111bcp.12458. 99. Bem JL, Dextromethorphan PR. An overview of safety troubles. Drug Saf. 1992;7(3):190. 100. Khalid S, Murdoch R, Newlands A, Clever K, Kelsall A, Holt K, et al. Transient receptor possible vanilloid 1 (TRPV1) antagonism in individuals with refractory chronic cough: a double-blind randomized controlled trial. J Allergy Clin Immunol. 2014;134(1):562. doi:10.1016 j.jaci.2014.01.038. 101. Niimi A. Cough, asthma, and cysteinyl-leukotrienes. Pulm Pharmacol Ther. 2013;26(five):514. doi:ten.1016j.pupt.2013.06.003. 102. Spector SL, Tan RA. Effectiveness of montelukast in the therapy of cough variant asthma. Ann Allergy Asthma Immunol. 2004;93(3):232. doi:ten.1016 S1081-1206(ten)61493-7. 103. Dicpinigaitis PV, Dobkin JB, Reichel J. Antitussive effect in the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J Asthma. 2002;39(four):291. 104. Kita T, Fujimura M, Ogawa H, Nakatsumi Y, Nomura S, Ishiura Y, et al. Antitussive effects of the leukotriene receptor antagonist montelukast in sufferers with cough variant asthma and atopic cough. Allergol Int. 2010;59(2):1852. doi:ten.2332allergolint.09-OA0112. 105. Cai C, He MZ, Zhong SQ, Tang Y, Sun BQ, Chen QL, et al. Add-on montelukast vs double-dose budesonide in nonasthmatic eosinophilic bronchitis: a pilot study. Respir Med. 2012;106(10):13695. doi:ten.1016 j.rmed.2012.06.009. 106. Chang AB, Winter D, Acworth JP. Leukotriene receptor antagonist for prolonged non-specific cough in children. Cochrane Database Syst Rev. 2006;two, CD005602. doi:10.100214651858.CD005602.pub.